Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Summary

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to evaluate the safety, tolerability, and PK of IGM-7354 in participants with relapsed and/or refractory tumors. The study design consists of a dose-escalation stage and dose-expansion stage. Study participation will consist of a 28-day screening period, a treatment period, and a safety follow-up period 90-days after the last dose.

Timeline

Start

2023-01-10

Primary completion

2024-05-31

Completion

2024-05-31

Drugs

Indications